Manostaxx
The text that follows is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
SOURCE: http://www.polarixpartner.com/files/content/publikationen/pdf/150430_White_Paper_Produktionseffizienz_Pharma_PXP_EN.pdf
Examining the costs structures of companies in the pharmaceuticals industry, there are significant differences between, say, a globally active, research-heavy organisation (approx. 30% of overall costs stemming from product manufacturing), a maker of generics (product manufacture costs at 50%), and a pure-breed supplier (approx. 60%). (See fig. 1)
Breaking down these manufacturing costs, the principle items on average are materials (approx. 44%), staffing (approx. 25%), and machinery, property, and facilities (approx.. 15%). (See fig. 2)
Previous benchmark studies for reference production sites have shown an average potential for 16% of savings, with the greatest differences being calculated for quality assurance (QA) / quality control (QC), maintenance, machinery use, and high productivity. (See fig. 3)
